Outcomes With Multi Parametric MRI (mpMRI) Compared to Diagnostic Transurethral Resection of Bladder Tumor (TURBT) in Patients With Suspected Muscle-Invasive Bladder Cancer - a Pilot Study

What this Trial Is About

Researchers are evaluating the accuracy of the VI-RADS score from multi-parametric magnetic resonance imaging (mpMRI) compared to the pathology results from diagnostic transurethral bladder tumor resection (TURBT) in patients suspected of having muscle-invasive bladder cancer. This pilot, single-arm, prospective study also compares clinical outcomes and quality of life between these two diagnostic methods. The goal is to understand how well mpMRI can detect muscle invasion in bladder cancer compared to the current standard TURBT procedure. Participants will undergo both mpMRI and the TURBT surgical procedure as part of the study. The mpMRI will provide a VI-RADS score indicating the likelihood of muscle invasion, and TURBT will provide pathological staging. This combined diagnostic approach allows researchers to compare imaging results directly to tissue pathology. The study will monitor patients for up to five years to evaluate progression-free survival, adverse events, quality of life, repeat surgeries, and healthcare costs related to each diagnostic method. During the study, participants will have scheduled visits for imaging, surgery, and follow-up assessments. Researchers will collect data on cancer progression, timing of treatments, and patient quality of life over time. They will also track any complications or additional procedures needed. The primary outcome is whether the mpMRI VI-RADS score matches the pathological muscle invasion found by TURBT within one year. Secondary outcomes include long-term cancer outcomes, safety, quality of life, and healthcare expenditures over up to five years.

mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer